Late-stage clinical biopharmaceutical company Geron Corporation is laser-focused on developing and commercializing therapeutic solutions for myeloid hematologic malignancies. Its promising telomerase inhibitor, imetelstat, is currently in Phase 3 clinical trials and aims to combat uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies. With the ultimate goal of treating low to intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis, Geron Corporation has been making groundbreaking strides in biopharmaceutical research since its incorporation in 1990. Headquartered in Foster City, California, this innovative company is poised to revolutionize the field of hematologic oncology.
Geron's ticker is GERN
The company's shares trade on the NASDAQ stock exchange
They are based in Menlo Park, California
There are 51-200 employees working at Geron
It is geron.com
Geron is in the Healthcare sector
Geron is in the Drug Manufacturers - Other industry
The following five companies are Geron's industry peers: